TRCT
RCUS icon

Tower Research Capital (TRC)’s Arcus Biosciences RCUS Stock Holding History

Tower Research Capital (TRC)’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$302K Buy
13,977
+9,152
+190% +$198K 0.01% 1295
2025
Q4 		$115K Sell
4,825
-2,224
-32% -$45.4K ﹤0.01% 1847
2025
Q3 		$95.9K Sell
7,049
-1,400
-17% -$14.6K ﹤0.01% 2023
2025
Q2 		$68.8K Buy
8,449
+5,476
+184% +$46.8K ﹤0.01% 2702
2025
Q1 		$23.3K Sell
2,973
-4,210
-59% -$48.8K ﹤0.01% 2820
2024
Q4 		$107K Buy
7,183
+456
+7% +$7.45K ﹤0.01% 2115
2024
Q3 		$103K Sell
6,727
-11,788
-64% -$186K ﹤0.01% 2213
2024
Q2 		$282K Buy
18,515
+17,928
+3,054% +$289K ﹤0.01% 1818
2024
Q1 		$11.1K Sell
587
-1,927
-77% -$33.3K ﹤0.01% 3605
2023
Q4 		$48K Sell
2,514
-2,270
-47% -$36.3K ﹤0.01% 3158
2023
Q3 		$85.9K Sell
4,784
-2,594
-35% -$52.1K ﹤0.01% 2092
2023
Q2 		$150K Buy
7,378
+3,490
+90% +$66.5K 0.01% 1755
2023
Q1 		$71K Sell
3,888
-3,246
-46% -$62K ﹤0.01% 2189
2022
Q4 		$147K Buy
7,134
+2,710
+61% +$74.6K 0.01% 1531
2022
Q3 		$115K Sell
4,424
-8,550
-66% -$226K ﹤0.01% 2449
2022
Q2 		$329K Buy
12,974
+10,428
+410% +$255K 0.01% 1416
2022
Q1 		$81K Sell
2,546
-2,050
-45% -$68.7K ﹤0.01% 2369
2021
Q4 		$186K Sell
4,596
-2,955
-39% -$115K ﹤0.01% 1828
2021
Q3 		$263K Buy
7,551
+2,922
+63% +$90.9K 0.01% 1553
2021
Q2 		$128K Sell
4,629
-46
-1% -$1.31K ﹤0.01% 2223
2021
Q1 		$131K Buy
4,675
+2,699
+137% +$93.9K ﹤0.01% 2360
2020
Q4 		$51K Sell
1,976
-4,992
-72% -$121K ﹤0.01% 3107
2020
Q3 		$119K Sell
6,968
-13,651
-66% -$305K ﹤0.01% 3016
2020
Q2 		$510K Buy
+20,619
New +$556K 0.02% 1017
2019
Q4 		– Sell
-1,052
Closed -$10K – 4223
2019
Q3 		$10K Buy
+1,052
New +$8.45K ﹤0.01% 2940
2019
Q2 		– Sell
-4,870
Closed -$61K – 4169
2019
Q1 		$61K Buy
+4,870
New +$52.9K ﹤0.01% 1675
2018
Q4 		– Sell
-56
Closed -$1K – 4260
2018
Q3 		$1K Sell
56
-2,160
-97% -$27.5K ﹤0.01% 3611
2018
Q2 		$27K Buy
+2,216
New +$34.8K ﹤0.01% 2242

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Tower Research Capital (TRC)'s RCUS Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Arcus Biosciences (RCUS) stake by 190% in Q1 2026, buying an estimated $198K and bringing the position to 13,977 shares worth $302K. The position accounts for 0.01% of the portfolio, ranked #1295.

Tower Research Capital (TRC) first reported a position in RCUS in Q2 2018 and has held it in 28 quarters since. The position peaked at $510K in Q2 2020. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Tower Research Capital (TRC) held 13,977 shares of Arcus Biosciences worth $302K as of Q1 2026.
  • Tower Research Capital (TRC) bought 9,152 Arcus Biosciences shares in Q1 2026, an estimated $198K.
  • Arcus Biosciences made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1295 holding.
  • Tower Research Capital (TRC) first reported a position in Arcus Biosciences in Q2 2018 and has held it in 28 quarters since.
  • Tower Research Capital (TRC)'s Arcus Biosciences position peaked at $510K in Q2 2020.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.